港股異動 | 中國新華教育跌逾6% 推遲收購富達公司股權
格隆匯11月25日丨中國新華教育(2779.HK)今日跳空低開,現報2.59港元,跌幅6.16%,暫成交805.5萬港元,最新總市值41.7億港元。
公司7月15日公告稱,擬收購通過收購富達公司60%股權從而收購海源學院和昆明市衞生學校兩所學校辦學舉辦者的60%權益。現由於海源學院由獨立學院轉設為獨立設置的民辦普通高校在時間安排上存在不確定性,各方同意待海源學院完成轉設之日起三個月內開始繼續推進。就上述收購而言,公司董事認為交易可使集團進一步拓展其學校網絡及加大市場滲透率,於收購後,集團的學生總數將進一步增加且進一步提升集團整體的盈利。公司股價在7月15日當天收漲6%,盤中衝高漲逾12%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.